BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Avian flu virus
,
Trichostatin A
,
rs7903146
,
FOXP1
,
calcium channel activity
,
Leukemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PAR 2
Summary
General Info
Curated Studies
Most Correlated Studies
PAR-2 activation in pancreatic cancer cell line BxPC-3
Gene expression profiling of KMS11 parental (PAR), TKO and 8 reconstituted lines
Pars tuberalis gene expression in mice subjected to long or short day cycles
Expression in Par-1 and Skn-1 mutants of C. elegans
Dopamine neurons of substantia nigra pars compacta from Parkinsons disease patients
Explore Curated Studies Results
Literature
Most Relevant Literature
Expression analysis of protease-activated receptor-2 in cats.
The cathepsin-S/protease-activated receptor-(PAR)-2 axis drives chronic allograft vasculopathy and i…
Uremic solutes of indoxyl sulfate and p-cresol enhance protease-activated receptor-2 expression in v…
Electrospun tube reduces adhesion in rabbit Achilles tendon 12 weeks post-surgery without PAR-2 over…
MicroRNA-205 Mediates Proteinase-Activated Receptor 2 (PAR2) -Promoted Cancer Cell Migration.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
A Comparison of Conventional Versus Digital PAR (Peer Assessment Rating) Scores Using an Intraoral S…
Platelet PAR-1 Activation in Health and Diabetes
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Aller…
Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Part…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ